This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
High Tide Inc. (HITI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
High Tide Inc. (HITI) reachead $2.54 at the closing of the latest trading day, reflecting a +0.4% change compared to its last close.
HealthEquity (HQY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 21.21% and 3.16%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of 15.15% and 2.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
High Tide Inc. (HITI) reachead $2.38 at the closing of the latest trading day, reflecting no change compared to its last close.
High Tide (HITI) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), High Tide (HITI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
by Zacks Equity Research
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
High Tide Inc. (HITI) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
High Tide Inc. (HITI) closed at $2.18 in the latest trading session, marking a -1.36% move from the prior day.
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
by Zacks Equity Research
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
Henry Schein (HSIC) Extends Partnership With Special Olympics
by Zacks Equity Research
Henry Schein's (HSIC) extended collaboration with Special Olympics is likely to promote wellness and health education for athletes with ID around the world.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).
Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -58.82% and 2.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts
by Zacks Equity Research
Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.
Why High Tide Inc. (HITI) Dipped More Than Broader Market Today
by Zacks Equity Research
High Tide Inc. (HITI) reachead $2.24 at the closing of the latest trading day, reflecting a -1.32% change compared to its last close.
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Expands Vascular Access Portfolio With New Launch
by Zacks Equity Research
Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.
Is High Tide (HITI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how High Tide Inc. (HITI) and Hologic (HOLX) have performed compared to their sector so far this year.
High Tide Inc. (HITI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw High Tide Inc. (HITI) settling at $2.16, representing a -1.37% change from its previous close.
How You Should Play Hologic (HOLX) Ahead of Q2 Earnings
by Riya Anand
Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.